- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Spinal muscular atrophy
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 935KB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 173KB)
Risdiplam – March 2023
Risdiplam: Powder for oral solution 0.75 mg per 1 mL, 80 mL; Evrysdi®
Last updated
30 June 2023